These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 16793840)

  • 41. Overexpression of synoviolin in peripheral blood and synoviocytes from rheumatoid arthritis patients and continued elevation in nonresponders to infliximab treatment.
    Toh ML; Marotte H; Blond JL; Jhumka U; Eljaafari A; Mougin B; Miossec P
    Arthritis Rheum; 2006 Jul; 54(7):2109-18. PubMed ID: 16802346
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
    Eriksson C; Engstrand S; Sundqvist KG; Rantapää-Dahlqvist S
    Ann Rheum Dis; 2005 Mar; 64(3):403-7. PubMed ID: 15297281
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis.
    Lequerré T; Gauthier-Jauneau AC; Bansard C; Derambure C; Hiron M; Vittecoq O; Daveau M; Mejjad O; Daragon A; Tron F; Le Loët X; Salier JP
    Arthritis Res Ther; 2006; 8(4):R105. PubMed ID: 16817978
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.
    Familian A; Voskuyl AE; van Mierlo GJ; Heijst HA; Twisk JW; Dijkmans BA; Hack CE
    Ann Rheum Dis; 2005 Jul; 64(7):1003-8. PubMed ID: 15958758
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept.
    Crnkic M; Månsson B; Larsson L; Geborek P; Heinegård D; Saxne T
    Arthritis Res Ther; 2003; 5(4):R181-5. PubMed ID: 12823852
    [TBL] [Abstract][Full Text] [Related]  

  • 46. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
    Buch MH; Seto Y; Bingham SJ; Bejarano V; Bryer D; White J; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):42-8. PubMed ID: 15641046
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice.
    Kneepkens EL; Plasencia C; Krieckaert CL; Pascual-Salcedo D; van der Kleij D; Nurmohamed MT; López-Casla MT; Wieringa R; Rispens T; Wolbink G
    Ann Rheum Dis; 2014 Dec; 73(12):2217-9. PubMed ID: 25261580
    [No Abstract]   [Full Text] [Related]  

  • 48. Impact of treatment with infliximab on anticyclic citrullinated peptide antibody and rheumatoid factor in patients with rheumatoid arthritis.
    Ahmed MM; Mubashir E; Wolf RE; Hayat S; Hall V; Shi R; Berney SM
    South Med J; 2006 Nov; 99(11):1209-15. PubMed ID: 17195414
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
    Comby E; Tanaff P; Mariotte D; Costentin-Pignol V; Marcelli C; Ballet JJ
    J Rheumatol; 2006 Jan; 33(1):24-30. PubMed ID: 16395746
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of infliximab treatment on insulin resistance in patients with rheumatoid arthritis.
    Oguz FM; Oguz A; Uzunlulu M
    Acta Clin Belg; 2007; 62(4):218-22. PubMed ID: 17849692
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
    Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
    J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab.
    Plasencia Ch; Pascual-Salcedo D; Alcocer P; Bonilla MG; Villalba A; Peiteado D; Arribas F; Díez J; Lopez-Casla MT; Martín-Mola E; Balsa A
    Ann Rheum Dis; 2013 Nov; 72(11):1888-90. PubMed ID: 23740237
    [No Abstract]   [Full Text] [Related]  

  • 53. Differential gene expression profiles may differentiate responder and nonresponder patients with rheumatoid arthritis for methotrexate (MTX) monotherapy and MTX plus tumor necrosis factor inhibitor combined therapy.
    Oliveira RD; Fontana V; Junta CM; Marques MM; Macedo C; Rassi DM; Passos GA; Donadi EA; Louzada-Junior P
    J Rheumatol; 2012 Aug; 39(8):1524-32. PubMed ID: 22753658
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis.
    Lindberg J; Wijbrandts CA; van Baarsen LG; Nader G; Klareskog L; Catrina A; Thurlings R; Vervoordeldonk M; Lundeberg J; Tak PP
    PLoS One; 2010 Jun; 5(6):e11310. PubMed ID: 20593016
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.
    Haraoui B; Cameron L; Ouellet M; White B
    J Rheumatol; 2006 Jan; 33(1):31-6. PubMed ID: 16395747
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone.
    Visvanathan S; Keenan GF; Baker DG; Levinson AI; Wagner CL
    J Rheumatol; 2007 May; 34(5):952-7. PubMed ID: 17444589
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients.
    Jamnitski A; Krieckaert CL; Nurmohamed MT; Hart MH; Dijkmans BA; Aarden L; Voskuyl AE; Wolbink GJ
    Ann Rheum Dis; 2012 Jan; 71(1):88-91. PubMed ID: 21914626
    [TBL] [Abstract][Full Text] [Related]  

  • 58. How does infliximab work in rheumatoid arthritis?
    Maini RN; Feldmann M
    Arthritis Res; 2002; 4 Suppl 2(Suppl 2):S22-8. PubMed ID: 12110154
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radiographic benefit without clinical improvement in infliximab-treated patients with rheumatoid arthritis: comment on the article by Smolen et al.
    Pincus T; Yazici Y; Yazici H; Kavanaugh AF; Kremer JM; Wolfe F
    Arthritis Rheum; 2005 Dec; 52(12):4044-5; author reply 4045-7. PubMed ID: 16320353
    [No Abstract]   [Full Text] [Related]  

  • 60. Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis.
    Bos WH; Bartelds GM; Vis M; van der Horst AR; Wolbink GJ; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Lems WF; Nurmohamed MT; Aarden L; Hamann D
    Ann Rheum Dis; 2009 Apr; 68(4):558-63. PubMed ID: 18445623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.